RD Biotech

RD-Biotech is a private, revenue-generating French CRO/CDMO specializing in custom services for biological reagents, including plasmid DNA, monoclonal and recombinant antibodies, proteins, and cell culture. Founded in 2002, it leverages multiple technological platforms to serve pharmaceutical and biotech clients in R&D, pre-clinical, and clinical studies, with a growing emphasis on GMP-grade manufacturing. The company combines strong technical expertise with a service-oriented model, producing hundreds of antibodies and plasmids annually for national and international clients.

Integrated CRO/CDMO platforms for molecular biology (plasmid DNA), immunology (monoclonal/recombinant antibody development), and cellular engineering (cell line development & culture). Includes recombinant protein expression, analytical services (LUMINEX, immunoassays), and new GMP-grade manufacturing capabilities.

RD-Biotech competes in the fragmented European CRO/CDMO market against large global players (e.g., Lonza, Catalent) and numerous specialized boutiques. Its differentiation lies in its broad technical scope across molecular biology, immunology, and cell culture, combined with a focus on personalized service and rapid turnaround, now augmented by GMP capabilities.